| 64.97 0.01 (0.02%) | 05-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 75.91 | 1-year : | 88.67 |
| Resists | First : | 65 | Second : | 75.91 |
| Pivot price | 64.79 |
|||
| Supports | First : | 64.62 |
Second : | 64.4 |
| MAs | MA(5) : | 64.96 |
MA(20) : | 64.74 |
| MA(100) : | 39.81 |
MA(250) : | 23.44 |
|
| MACD | MACD : | 3  |
Signal : | 3.9 |
| %K %D | K(14,3) : | 94.6 |
D(3) : | 96.3 |
| RSI | RSI(14): 83.3 | |||
| 52-week | High : | 65 | Low : | 8.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ALPN ] has closed below upper band by 23.1%. Bollinger Bands are 94% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 65.12 - 65.44 | 65.44 - 65.7 |
| Low: | 64.06 - 64.51 | 64.51 - 64.87 |
| Close: | 64.35 - 65.02 | 65.02 - 65.56 |
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Mon, 20 May 2024
Fenwick Represents Alpine Immune Sciences in its Acquisition by… - fenwick.com
Fri, 10 May 2024
Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ... - Yahoo Finance
Fri, 12 Apr 2024
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex - Nasdaq
Wed, 10 Apr 2024
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch - Investopedia
Wed, 10 Apr 2024
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences - Business Wire
Mon, 18 Mar 2024
Alpine Immune Sciences Inc (ALPN) Reports Full Year 2023 Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 99.4 (%) |
| Shares Short | 3,890 (K) |
| Shares Short P.Month | 5,280 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.07 |
| Profit Margin | -65.2 % |
| Operating Margin | -322.8 % |
| Return on Assets (ttm) | -10.2 % |
| Return on Equity (ttm) | -14.7 % |
| Qtrly Rev. Growth | -25.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.82 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -101.52 |
| PEG Ratio | 0 |
| Price to Book value | 12.81 |
| Price to Sales | 78.85 |
| Price to Cash Flow | -55.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|